

DAFTAR PUSTAKA

- Adrianjah, H dan Adam, J. 2006. Sindroma Metabolik: Pengertian, Epidemiologi, dan Kriteria Diagnosis. *Informasi Laboratorium Prodia* ;(4).
- Antoniou, A., Pharoah, P., Narod, S. 2003. Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. *Am. J. Hum. Genet.*, 72, pp. 1117–1130.
- Aryandono, T. 2006. Faktor Prognosis Kanker Payudara Operabel di Yogyakarta. Disertasi. Pasca Sarjana Universitas Gadjah Mada.
- Balsan, G. A., Veira, J., Oliveira, A. 2015. Relationship between adiponectin, obesity and insulin resistance', *Revista da Associação Médica Brasileira*, 61(1), pp. 72–80.
- Bartelink, H., Maingon, P., Poortmans, P., *et al.* 2015. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer : 20-year follow-up of a randomized phase 3 trial. *Lancet Oncol.* Jan (e 9Dec);16(1):47-56.
- Basaran, G., Turhal, N., Cabuk, D. 2011. Weight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey', *Medical Oncology*, 28(2), pp. 409–415.
- Brochu-Gaudreau, K., Rehfedt, C., Blouin, R. 2010. Adiponectin action from head to toe', *Endocrine*, 37(1), pp. 11–32.
- Burstein, H. J. 2005. The Distinctive Nature of HER2-Positive Breast Cancer. *N engl j med* 353;16 october 20. pp. 1652–1654.
- Burstein, H.J., Prestrud, A.A., Seidenfeld, J., Anderson, H., Buchholz, T.A., Davidson, N.E., Gelmon, K.E., Giordano, S.H., Hudis, C.A., Malin, J., Mamounas, E.P., Rowden, D., Solky, A.J., Sowers, M.R., Stearns, V., Winer, E.P., Somerfield, M.R., Griggs, J.J. 2010 American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. *J Clin Oncol* 28:3784–3796
- Caan. 2007. Post Diagnosis Weight Gain and Breast Cancer Recurrence In Women with Early Stage Breast Cancer, p. 530. doi: 10.1111/j.1365-2648.2008.04878.x/abstract.
- Camoriano J.K, Loprinzi C.L, Ingle J.N, et al. 1990. Weight change in women treated with adjuvant therapy or observed following mastectomy for node positive breast cancer. *J Clin Oncol* ;8:1327–1334.

- Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. 2000. Estrogens as endogenous genotoxic agents — DNA adducts and mutations. In: Estrogens as endogenous carcinogens in the breast and prostate. *Journal of the National Cancer Institute monograph*. No. 27. Bethesda, Md.: National Cancer Institute, July:75-93.
- Chlebowski, RT., Blackburn, G., Thomson, C. 2006. Dietary fat reduction and breast cancer outcome : Interim efficacy results from the women's intervention nutrition study. *Journal of the National Cancer Institute*, 98(24), pp. 1767–1776.
- Cooke, P. S. dan Naaz, A. 2004. Role of estrogens in adipocyte development and function. *Experimental biology and medicine*. 229(11), pp. 1127–1135.
- Copson, E.R., Cutress, R.I., Maishman, T., *et al.* 2015. Obesity and the outcome of young breast cancer patients in the UK. The POSH study. *Ann Oncol.* ; 26 (1):101-12.
- Dahlan, M.S. 2016. Langkah-langkah membuat proposal penelitian bidang kedokteran dan kesehatan. Seri 3 ed. 4.Sagung Seto. Hal 81.
- Dai, X., Chen, A. and Bai, Z. 2015. Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling. *Scientific Reports*. 4(1), p. 6566.
- Dai, X, Xiang, L., Li, T. 2016. Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes, *Journal of Cancer*, 7(710), pp. 1281–1294.
- Derks, M. Blok, Eseyneave, C. 2017. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. *The Lancet Oncology* vol 18 issue 9 pp 1211-1220.
- Dignam, J. J., Wieand, K., Johnson, K. 2007. Obesity , Tamoxifen Use , and Outcomes in Women With Estrogen Receptor – Positive Early-Stage Breast Cancer, 95(19). doi: 10.1093/jnci/djg060.
- Ernst, M. dan Putoczki, T.L. 2012. Stat3: linking inflammation to (gastrointestinal) tumourigenesis. *Clin Exp Pharmacol Physiol* 39(8):711–718.
- Fattah, M. 2006. Sindroma Metabolik dan Penanda Baru Disfungsi Endotel: Asimetrik Dimetil Arginin (ADMA) dan High Sensitivity C-Reactive Protein (Hs-CRP). *Forum Diagnosticum*; (1).
- Folkerd, E., Dixon, J., Renshaw, L. 2012. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. *Journal of Clinical Oncology* vol 30, issue 24 pp2977 - 2980
- Frank, A., Brown, L., dan Clegg, D. 2008. The Role of Hypothalamic Estrogen Receptors in Metabolic Regulation, *North*, 29(10), pp. 1883–1889. doi:

10.3174/ajnr.A1256.Functional.

- Frasca, F., Pandini, G., Scalia, P., et al., 1999. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. *Mol Cell Biol*;19:3278-88.
- Garreau, J. R., De La Melena, T., Walt, D., Karamlou, K., Johnson, N. 2006. Side effects of aromatase inhibitors versus tamoxifen: the patients perspective. *American Journal of Surgery*, 192(4), pp. 496–498.
- Globocan, 2012. Breast Cancer Estimated incidence, mortality and Prevalence Worldwide in 2012. www.globocan.oarc.fdu.edu/old/factsheets/cancers/breast-new.asp
- Gonzalez, R.R., Cherfils, S., Escobar, M., Yoo, J.H., Carino, C., Styer, A.K., Sullivan, B.T., Sakamoto, H., Olawaiye, A., Serikawa, T., Lynch, M.P., Rueda. B.R. 2006. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). *J Biol Chem* 281(36):26320–26328.
- Goodwin P, Ennis M, Pritchard K, et al.1990. Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. *J Clin Oncol* ;17(1):120–129.
- Hamed. E.A., Zakhary, M.M., Maximous, D.W. 2012. Apoptosis, angiogenesis, inflammation, and oxidative stress: basic interactions in patients with early and metastatic breast cancer. *J Cancer Res Clin Oncol* 138(6):999–1009.
- Holm, J. Eriksson, A., Ploner, A. 2017. Assessment of Breast Cancer Risk Factors Reveals Subtype Heterogeneity. *Cancer research*. American Association for Cancer Research, 77(13), pp. 3708–3717.
- Hong, S., Didwania, A., Olopade, O. 2009. The Expanding Use of Third-Generation Aromatase Inhibitors: What the General Internist Needs to Know, pp. 383–388. doi: 10.1007/s11606-009-1037-2.
- Hubalek, M., Oberguggenberger, B., Beer, A., Meraner, B. 2014. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels. *Clinical Breast Cancer* vol 14, issue 4 pp 291 - 296
- Iliopoulos, D., Hirsch, H.A., Wang, G., Struhl, K. 2011. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. *Proc Natl Acad Sci U S A* 108(4):1397–1402.
- Kalluri, R dan Weinberg, R. A. 2009. The basics of epithelial-mesenchymal transition. *J Clin Invest* 119(6):1420–1428.
- Kang, J. H., Lee, Y., Yu, B. 2005. Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. *Archives of Pharmacol*

Research, 28(11), pp. 1263–9.

- Kemp, A., Preen, D., Saunders, C. 2014. Women Commencing Anastrozole , Letrozole or Tamoxifen for Early Breast Cancer: The Impact of Comorbidity and Demographics on Initial Choice. 9(1). doi: 10.1371/journal.pone.0084835.
- Keum, N., Greenwood, D,C., Lee, D,H., 2015. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. *J Natl Cancer Inst*;107(3):dju428.
- Khambri, D. 2015. Peran terapi hormonal pada kanker payudara. *Majalah Kedokteran Andalas*, Vol. 38, No. Supl. 1, Agustus 2015.
- Komite Penanggulangan Kanker Nasional, 2017. Panduan Penatalaksanaan Kanker Payudara. Kementerian Kesehatan Republik Indonesia.
- Kroenke, C. H., Chen, W., Rosner, B., *et al.* 2005. Weight, weight gain, and survival after breast cancer diagnosis. *Journal of Clinical Oncology*, 23(7), pp. 1370–1378.
- Kumar, NB., Allen, K., Cantor, A., *et al.* 1997. Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer : fact or artifact ?. pp. 135–136.
- Lahart, IM., Metsios, G., Nevill, A., Alan, M. 2015. Physical activity, risk of death and recurrence in breast cancer survivors: A systematic review and meta-analysis of epidemiological studie. *Acta Oncologica*, 54(5), pp. 635–654.
- Lanari, C, Lamb, C,A., Fabris, V,T., Helguero, L,A., Soldati, R., Bottino, MC, *et al.* 2009. The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. *Endocrine-related cancer* ; 16: 333-50.
- Lauring, J., Wolff, A,C. 2016. Evolving Role of the Estrogen Receptor as a Predictive Biomarker: ESR1 Mutational Status and Endocrine Resistance in Breast Cancer. *J Clin Oncol*, Vol 34,25 (Sept 1):2950-2952.
- Levine, EG., Raczynski, J. M. and Carpenter, J. T. 1991. Weight gain with breast cancer adjuvant treatment.. *Cancer*, 67(7), pp. 1954–1959.
- Li, Y., Yao, J., Chang, M., *et al.*, 2004. Equine catechol estrogen 4-hydroxyequilenin is a more potent inhibitor of the variant form of catechol-O-methyltransferase. *Chem Res Toxicol* ;17:512-20.
- Lipscombe, LL., Fischer, H.D., dan Rochon, P. A. 2012. Association Between Tamoxifen Treatment and Diabetes’, pp. 2615–2622. doi: 10.1002/cncr.26559.
- Lizcano, F. dan Guzmán, G. 2014. Estrogen Deficiency and the Origin of Obesity during Menopause. Hindawi Publishing Corporation: *BioMed Research*

International Vol. 2014, Article ID 757461, 11 pages.

- Lorizio, A. Wu, M. Beattie, H. Rugo, S. Tchu, K. Kerlikowske, E. Z. 2013. Clinical and biomarker predictors of side effects from tamoxifen, 132(3), pp. 1107–1118. doi: 10.1007/s10549-011-1893-4.
- Lumachi, F., Brunello, A., Maruzzo, M., *et al.* 2013. Treatment of Estrogen Receptor-Positive Breast Cancer. *Current Medicinal Chemistry*, 20(5), pp. 596–604
- Lx, M., Mk, B., Sy, T., *et al.* 2016. Body weight management in overweight and obesity breast cancer survivors (Protocol). (3) . doi: 10.1002/14651858.CD012110. www.cochranelibrary.com.
- Mahmood, U., Morri, s C., Neuner, G., *et al.* 2012 Similar survival with breast conservation therapy or mastectomy in the management of young women with early-stage breast cancer. *Int J Radiol Oncol Biol Phys.*;83:1387-93.
- Makari-judson, G., Braun, B., Jerry, D., *et al.* 2014. Weight gain following breast cancer diagnosis: Implication and proposed mechanisms. 5(3), pp. 272–283.
- Mariel, GC., Pilar, CTI., Elena, CR., Nancy, GD., Guadalupe, RM., Ignacio, MSM., *et al.*, 2018. Expression of NK cell surface receptors in breast cancer tissue as predictors of resistance to antineoplastic treatment. *Technology in Cancer Research and Treatment*, 17, pp. 1–11.
- Mittendorf, E,A., Buchholz, T,A., Tucker, S,L., *et al.* 2013. Impact of chemotherapy sequencing on loco-regional failure risk in breast cancer patients undergoing therapy. *Ann Surg* ; 257:173-9.
- Miyoshi, Y. 2003. Association of serum adiponectin levels with breast cancer risk. *Clin. Cancer Res.*, 9, pp. 5699–5704.
- Moore, KL, Arthur F. Dalley, A. M. R. Agur. 2013. Clinically Oriented Anatomy. Lippincot Williams and Wilkins, ed 7: p 105.
- Munsell, M,F., Sprague, B,L., Berry, D,A., Chisholm, G., Trentham-Dietz, A. 2014. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. *Epidemiol Rev*;36:114-136.
- Musatov, S., Chen, W., Pfaff, D., *et al.* 2007. Silencing of estrogen receptor in the ventromedial nucleus of hypothalamus leads to metabolic syndrome. *Proceedings of the National Academy of Sciences*, 104(7), pp. 2501–2506.
- Nam, S., Park, S., Park, H,S., Kim, S., Kim, J, Y., Kim, S, I. 2016. Association Between Insulin Resistance and Luminal B Subtype Breast Cancer in Postmenopausal Women. *Medicine* 95(9):e2825

- Neri, A., Marelli, D., Rossi, S., et al. 2007. Breast Cancer Local Recurrence: Risk Factors and Prognostic Relevance of Early Time to Recurrence. *World J Surg* 31: 36–45.
- Niraula, S., Ocana, A., Ennis, M. 2012. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: A meta-analysis. *Breast Cancer Research and Treatment*, 134(2), pp. 769–781. doi: 10.1007/s10549-012-2073-x
- Nyrop, K. A., Williams, G., Muss, H., et al. 2016. Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?. *Breast Cancer Research and Treatment*. Springer US, 158(2), pp. 203–217.
- Osborne, B. C. K., Zhao, H. H., dan Fuqua, S. A. W. 2016. Selective Estrogen Receptor Modulators : Structure , Function , and Clinical Use. 18(17), pp. 3172–3186.
- Pantschenko, A. G., Pushkar, I., Anderson, K. H., Wang, Y., Miller, L. J., Kurtzman, S. H., Kreutzer, D. L. 2003. The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. *Int J Oncol* 23(2):269–284.
- Playdon, M. C., Bracken, M., Sanft, T., et al. 2015. Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis. *Journal of the National Cancer Institute*, 107(12), p. 275.
- Renehan, A.G., Tyson, M., Egger, M., Heller, R.F., Zwahlen, M. 2014. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet* ;371(9612):569-578.
- Schvartsman, G., Gutierrez-barrera, A., Peterson, S., et al. 2017. Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomes. pp. 2515–2522.
- Sendur, M. A. N., Aksoy, S., Ozdemir, NY., Zengin, N., et al. 2016. Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor positive breast cancer. *Journal of B.U.ON*. 21(1), pp. 27–34.
- Sestak, I., Howell, A., Harvie, MN., Forbes, JF. 2012. Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. *Breast Cancer Research and Treatment*. 134(2), pp. 727–734.
- Sobral-Leite, M., Salomon, I., Mark, Opdam., Dinja, Kruger., et al. 2019. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. *Breast Cancer Research*. 21(1), pp. 1–12.
- Slowik, S., Fraczek, P., Krzemieiecki, K. 2016. Body mass index and aromatase

inhibitors: A step forward in individualizing therapy for breast cancer patients? *Expert Review of Anticancer Therapy* vol 16 ; 7, pp759 – 766.

Standish, L.J., Sweet, E.S., Novack, J., Wenner, C.A., Bridge, C., et al. 2008. Breast cancer and the immune system. *Journal of the Society for Integrative Oncology*, 6(4), pp. 158–168.

Stendahl, M., Ryden, L., Nordenskjold, B., Jonsson, P. E., Landberg, G., Jirstrom, K. 2006 High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. *Clinical cancer research : an official journal of the American Association for Cancer Research*; 12: 4614-8.

Stevens, J., Truesdale, K., Mc Clain, J., et al. 2006. The definition of weight maintenance. *International Journal of Obesity*, 30(3), pp. 391–399.

Suhardjo. 1990. Petunjuk Laboratorium Penelitian Keadaan Gizi Masyarakat. PAU Pangan dan Gizi IPB.

Suk Han, H., Wook Lee, K., Hyun Kim, J., Won Kim, S., Ah Kim, I., Youn Oh, D. 2008. Weight changes after adjuvant treatment in korean women with early breast cancer. *Breast Cancer and Research Treatment*.

Surmacz, E. dan Otvos, L. 2015. Molecular targeting of obesity pathways in cancer. *Hormone Molecular Biology and Clinical Investigation*, 22(2), pp. 53–62

Sun, H., Zou, J., Chen, L., Zu, X., Wen, G., Zhong, J. 2017. Triple-negative breast cancer and its association with obesity. *Molecular and clinical oncology*, pp. 935–942.

Suyono, S. 2007. Kecenderungan Peningkatan Jumlah Penyandang Diabetes dalam Penatalaksanaan Diabetes Mellitus Terpadu. Jakarta : Balai Penelitian FKUI, hal 1 – 5.

Takada, M., Saji, S., Masuda, N. 2012. Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. *Breast vol 21;1,pp 40 - 45*

Tanko, L., Bruun, J., Alexandersen, P. et al. 2004. Novel associations between bioavailable estradiol and adipokines in elderly women with different phenotypes of obesity: Implications for atherogenesis. *Circulation*, 110(15), pp. 2246–2252.

Trivers, K. F., Lund, M. J. Dan Eley, J. W. 2016. The Epidemiology of triple-negative breast cancer, including race. *HHS Public Access*, 20(7), pp. 1071–1082.

Turkoz, F. P., Solak, M., Petekkaya, I., Keskin, O. .2013. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women.

Journal of B.U.ON., 18(2), pp. 335–341.

- Van Erkelens, A. *et al.* 2017. Lifestyle Risk Factors for Breast Cancer in BRCA1/2-Mutation Carriers Around Childbearing Age. *J Genet Counsel*, 26, pp. 785–791. doi: 10.1007/s10897-016-0049-4.
- Vella V, Pandini G, Sciacca L, et al. 2002. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. *J Clin Endocrinol Metab*;87:245-54.
- Voogh, A,C., Nielsen, M., Peterse, J,L., *et al.* 2001. Differences in risk factors for Local and Distant Recurrence after Breast Conserving Therapy or Mastectomy for Stage I and II Breast Cancer: Pooled Results of Two Large European Randomised Trials. *T Clinical Oncology*. March;19(6):1688-97.
- Walker, R,A. 2008. Immunohistochemical markers as predictive tools for breast cancer. *Journal of clinical pathology*.; 61: 689-96.
- Weigelt, B., Baehner, F. L. and Reis-Filho, J. S. 2009. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. *The Journal of Pathology*.220(2)
- Widschwendter, P., Friedl, T., Schwentner, L, DeGregorio, N., *et al.* 2015. The influence of obesity on survival in early, high-risk breast cancer: Results from the randomized SUCCESS A trial. *Breast Cancer Research.*, 17(1), pp. 1–11.
- Van Erkelens, A., Derks, L., Sie, A., *et al.* 2017. Lifestyle Risk Factors for Breast Cancer in BRCA1/2-Mutation Carriers Around Childbearing Age?, *J Genet Counsel*, 26, pp. 785–791.
- Yu, K., Wu, J., Shen, Z., Shao, Z. 2012. Hazard of Breast Cancer-Specific Mortality among Women with Estrogen Receptor-Positive Breast Cancer after Five Years from Diagnosis: Implication for Extended Endocrine Therapy. *J Clin Endocrinol Metab* 97: E2201–E2209.